ALMS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

2 Analyst Rating

Wall Street analysts forecast ALMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALMS is 19.50 USD with a low forecast of 14.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

14.00

Averages

19.50

High

25.00

Current: 0.000

Low

14.00

Averages

19.50

High

25.00

H.C. Wainwright

Buy

maintain

$20 -> $40

2026-01-09

New

Reason

H.C. Wainwright

Price Target

$20 -> $40

2026-01-09

New

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Alumis to $40 from $20 and keeps a Buy rating on the shares. The firm says the Phase 3 envudeucitinib readout "reset expectations" for the oral TYK2 landscape. It cites reduced approval risk and a higher revenue ceiling for the target doubling.

Guggenheim

Yatin Suneja

NULL -> Buy

upgrade

$18 -> $32

2026-01-07

New

Reason

Guggenheim

Yatin Suneja

Price Target

$18 -> $32

2026-01-07

New

upgrade

NULL -> Buy

Reason

Guggenheim analyst Yatin Suneja raised the firm's price target on Alumis (ALMS) to $32 from $18 and keeps a Buy rating on the shares following the company's positive Phase 3 ONWARD-1/-2 study results. Takeda (TAK) is also conducting studies in PsA, Vitiligo, and HS, which could pioneer multibillion-dollar opportunity for envudeucitinib given its superior pharmacological properties over Sotyktu and Zasocitinib, as demonstrated by yesterday's PsO readout, the analyst tells investors.

Morgan Stanley

NULL -> Overweight

maintain

$22 -> $33

2026-01-07

New

Reason

Morgan Stanley

Price Target

$22 -> $33

2026-01-07

New

maintain

NULL -> Overweight

Reason

Morgan Stanley raised the firm's price target on Alumis to $33 from $22 and keeps an Overweight rating on the shares after the company reported positive topline results from the Phase 3 ONWARD program evaluating lead asset envudeucitinib in moderate-to-severe plaque psoriasis. Data for envudeucitinib in PsO "look competitive," says the analyst, who raised the firm's view of the probability for success for the indication to 80% from 60%.

Wells Fargo

Derek Archila

Overweight

maintain

$17 -> $39

2026-01-06

New

Reason

Wells Fargo

Derek Archila

Price Target

$17 -> $39

2026-01-06

New

maintain

Overweight

Reason

Wells Fargo analyst Derek Archila raised the firm's price target on Alumis to $39 from $17, while keeping an Overweight rating on the shares after the company announced topline results from its Phase 3 ONWARD1 and ONWARD2 clinical trials of envudeucitinib, a next-generation highly selective oral tyrosine kinase 2 inhibitor, in patients with moderate-to-severe plaque psoriasis. The firm believes envudeucitinib's positive PsO data strengthens the investment narrative beyond its original SLE-centric thesis, and will be a key competitor in PsO.

Oppenheimer

Jeff Jones

Outperform

maintain

$25 -> $50

2026-01-06

New

Reason

Oppenheimer

Jeff Jones

Price Target

$25 -> $50

2026-01-06

New

maintain

Outperform

Reason

Oppenheimer analyst Jeff Jones raised the firm's price target on Alumis to $50 from $25 and keeps an Outperform rating on the shares after the company reported positive results from the pivotal ONWARD trial of envudeucitinib. The firm sees Alumis agent "as highly competitive and potentially superior to icotrokinra on some endpoints," the analyst tells investors.

Leerink

NULL

Outperform

upgrade

$20 -> $32

2026-01-06

New

Reason

Leerink

Price Target

$20 -> $32

2026-01-06

New

upgrade

NULL

Outperform

Reason

Leerink raised the firm's price target on Alumis to $32 from $20 and keeps an Outperform rating on the shares.

Valuation Metrics

The current forward P/E ratio for Alumis Inc (ALMS.O) is -2.71, compared to its 5-year average forward P/E of -1.57. For a more detailed relative valuation and DCF analysis to assess Alumis Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.57

Current PE

-2.71

Overvalued PE

-1.04

Undervalued PE

-2.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.30

Current EV/EBITDA

-1.76

Overvalued EV/EBITDA

0.41

Undervalued EV/EBITDA

-3.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

25.42

Current PS

90.85

Overvalued PS

60.87

Undervalued PS

-10.03

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ALMS News & Events

Events Timeline

No data

News

8.5

01-09Globenewswire

PinnedAlumis Inc. Closes $345.1 Million Upsized Public Offering

8.5

01-08Benzinga

Alumis Inc. Prices 17.65M Shares at $17 Each, Raising Approximately $300M

8.5

01-08Globenewswire

Alumis Inc. Prices Upsized Public Offering of 17.65 Million Shares, Raising Approximately $300 Million

People Also Watch

Frequently Asked Questions

What is Alumis Inc (ALMS) stock price today?

The current price of ALMS is 19.56 USD — it has increased 7.59 % in the last trading day.

What is Alumis Inc (ALMS)'s business?

Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.

What is the price predicton of ALMS Stock?

What is Alumis Inc (ALMS)'s revenue for the last quarter?

Alumis Inc revenue for the last quarter amounts to 2.07M USD, decreased % YoY.

What is Alumis Inc (ALMS)'s earnings per share (EPS) for the last quarter?

Alumis Inc. EPS for the last quarter amounts to -1.06 USD, decreased -38.01 % YoY.

What changes have occurred in the market's expectations for Alumis Inc (ALMS)'s fundamentals?

The market is revising Downward the revenue expectations for Alumis Inc. (ALMS) for FY2025, with the revenue forecasts being adjusted by -1.36% over the past three months. During the same period, the stock price has changed by 331.79%.

How many employees does Alumis Inc (ALMS). have?

Alumis Inc (ALMS) has 168 emplpoyees as of January 10 2026.

What is Alumis Inc (ALMS) market cap?

Today ALMS has the market capitalization of 2.39B USD.